Filtered By:
Specialty: Neurology
Condition: Patent Foramen Ovale
Cancer: Brain Cancers

This page shows you your search results in order of date.

Order by Relevance | Date

Total 4 results found since Jan 2013.

From cryptogenic to ESUS: Toward precision medicine?
Rev Neurol (Paris). 2022 May 18:S0035-3787(22)00592-6. doi: 10.1016/j.neurol.2022.01.016. Online ahead of print.ABSTRACTCryptogenic infarctions are infarctions without a defined cause, despite a complete work-up. They differ from infarctions of undetermined causes, which may involve overlapping causes or an incomplete investigation. It is also different from uncommon heritable and non-heritable causes. The term embolic stroke of undetermined source (ESUS) proposed in 2014 is defined as a non-lacunar brain infarct without proximal arterial stenosis or cardioembolic sources. The major advantage of this definition compared to...
Source: Revue Neurologique - May 21, 2022 Category: Neurology Authors: S Timsit Source Type: research

Diagnostic and Management Challenges in Patients with Left Atrial Myxoma (P1.229)
Conclusions:Cardiac myxomas are rare tumors, mostly arising from the left atrium that may cause ischemic or hemorrhagic strokes, intracranial aneurysms, or myxomatous metastases.Disclosure: Dr. Orjuela has nothing to disclose. Dr. McGinley has nothing to disclose. Dr. Sweis has nothing to disclose. Dr. Prabhu has nothing to disclose. Dr. Bakhos has nothing to disclose. Dr. Biller has received personal compensation in an editorial capacity for the Journal of Stroke and Cerebrovascular Diseases, Frontier in Neurology and Up-To-Date.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Orjuela, K., McGinley, M., Sweis, R., Prabhu, V., Bakhos, M., Biller, J. Tags: Cardiac Mechanisms and Complications of Stroke Source Type: research

A Case of Multiple Recurrent Ischemic Stroke in a Patient with Cholangiocarcinoma and Initiation of Anticoagulation Therapy for Secondary Stroke Prevention (P4.342)
CONCLUSIONS: Initiation of anticoagulation therapy and the optimal medications for secondary stroke prevention in cancer associated stroke remain controversial. Further randomized prospective studies are needed to establish treatment guidelines.Disclosure: Dr. Cheng has nothing to disclose. Dr. Then has nothing to disclose.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Cheng, J. Z., Then, R. Tags: Cerebrovascular Case Reports Source Type: research